• 1
    Rubanyi GM, Polokoff MA. Endothelins: molecular biology, biochemistry, pharmacology, physiology, and pathophysiology. Pharmacol Rev 1994; 46: 325415.
  • 2
    Kohan DE. Endothelins in the kidney: physiology and pathophysiology. Am J Kidney Dis 1993; 22: 493510.
  • 3
    Battistini B, Chailler P, D'Orleans-Juste P, Briere N, Sirois P. Growth regulatory properties of endothelins. Peptides 1993; 14: 38599.
  • 4
    Gershon MD. Endothelin and the development of the enteric nervous system. Clin Exp Pharmacol Physiol 1999; 26: 9858.
  • 5
    Sampaio AL, Rae GA, Henriques MM. Role of endothelins on lymphocyte accumulation in allergic pleurisy. J Leukoc Biol 2000; 67: 18995.
  • 6
    Salani D, Taraboletti G, Rosano L, et al. Endothelin-1 induces an angiogenic phenotype in cultured endothelial cells and stimulates neovascularization in vivo. Am J Pathol 2000; 157: 170311.
  • 7
    Baynash AG, Hosoda K, Giaid A, et al. Interaction of endothelin-3 with endothelin-B receptor is essential for development of epidermal melanocytes and enteric neurons. Cell 1994; 79: 127785.
  • 8
    Nakamura T, Ebihara I, Fukui M, Tomino Y, Koide H. Effect of a specific endothelin receptor A antagonist on mRNA levels for extracellular matrix components and growth factors in diabetic glomeruli. Diabetes 1995; 44: 8959.
  • 9
    Rockey DC. Vascular mediators in the injured liver. Hepatology 2003; 37: 412.
  • 10
    Ehrenreich H, Anderson RW, Fox CH, et al. Endothelins, peptides with potent vasoactive properties, are produced by human macrophages. J Exp Med 1990; 172: 17418.
  • 11
    Rockey D. Endothelin in hepatic fibrosis – friend or foe? Hepatology 1996; 23: 1698700.
  • 12
    Moncada S, Higgs A. The L-arginine-nitric oxide pathway. N Engl J Med 1993; 329: 200212.
  • 13
    Lowenstein CJ, Glatt CS, Bredt DS, Snyder SH. Cloned and expressed macrophage nitric oxide synthase contrasts with the brain enzyme. Proc Natl Acad Sci U S A 1992; 89: 67115.
  • 14
    Sessa WC, Harrison JK, Barber CM, et al. Molecular cloning and expression of a cDNA encoding endothelial cell nitric oxide synthase. J Biol Chem 1992; 267: 152746.
  • 15
    Wiest R, Groszmann RJ. The paradox of nitric oxide in cirrhosis and portal hypertension: too much, not enough. Hepatology 2002; 35: 47891.
  • 16
    Sanz-Cameno P, Medina J, Garcia-Buey L, et al. Enhanced intrahepatic inducible nitric oxide synthase expression and nitrotyrosine accumulation in primary biliary cirrhosis and autoimmune hepatitis. J Hepatol 2002; 37: 7239.
  • 17
    Hokari A, Zeniya M, Esumi H, Kawabe T, Gershwin ME, Toda G. Detection of serum nitrite and nitrate in primary biliary cirrhosis: possible role of nitric oxide in bile duct injury. J Gastroenterol Hepatol 2002; 17: 30815.
  • 18
    Yamamoto K, Akbar SM, Masumoto T, Onji M. Increased nitric oxide (NO) production by antigen-presenting dendritic cells is responsible for low allogeneic mixed leucocyte reaction (MLR) in primary biliary cirrhosis (PBC). Clin Exp Immunol 1998; 114: 94101.
  • 19
    Battista S, Bar F, Mengozzi G, et al. Evidence of an increased nitric oxide production in primary biliary cirrhosis. Am J Gastroenterol 2001; 96: 86975.
    Direct Link:
  • 20
    Stamler JS, Singel DJ, Loscalzo J. Biochemistry of nitric oxide and its redox-activated forms. Science 1992; 258: 1898902.
  • 21
    Ludwig J, Dickson ER, McDonald GS. Staging of chronic nonsuppurative destructive cholangitis (syndrome of primary biliary cirrhosis). Virchows Arch A Pathol Anat Histol 1978; 379: 10312.
  • 22
    Goto K. Basic and therapeutic relevance of endothelin-mediated regulation. Biol Pharm Bull 2001; 24: 121930.
  • 23
    Notas G, Xidakis C, Valatas V, Kouroumalis A, Kouroumalis E. Levels of circulating endothelin-1 and nitrates/nitrites in patients with virus-related hepatocellular carcinoma. J Viral Hepat 2001; 8: 639.
  • 24
    Wiest R, Groszmann RJ. Nitric oxide and portal hypertension: its role in the regulation of intrahepatic and splanchnic vascular resistance. Semin Liver Dis 1999; 19: 41126.
  • 25
    Pinzani M, Milani S, De Franco R, et al. Endothelin 1 is overexpressed in human cirrhotic liver and exerts multiple effects on activated hepatic stellate cells. Gastroenterology 1996; 110: 53448.
  • 26
    Clemens MG, Zhang JX. Regulation of sinusoidal perfusion: in vivo methodology and control by endothelins. Semin Liver Dis 1999; 19: 38396.
  • 27
    Moore K, Wendon J, Frazer M, Karani J, Williams R, Badr K. Plasma endothelin immunoreactivity in liver disease and the hepatorenal syndrome. N Engl J Med 1992; 327: 17748.
  • 28
    Gulberg V, Gerbes AL, Vollmar AM, Paumgartner G. Endothelin-3 like immunoreactivity in plasma of patients with cirrhosis of the liver. Life Sci 1992; 51: 11659.
  • 29
    Asbert M, Gines A, Gines P, et al. Circulating levels of endothelin in cirrhosis. Gastroenterology 1993; 104: 148591.
  • 30
    Gerbes AL, Moller S, Gulberg V, Henriksen JH. Endothelin-1 and -3 plasma concentrations in patients with cirrhosis: role of splanchnic and renal passage and liver function. Hepatology 1995; 21: 7359.
  • 31
    Uchihara M, Izumi N, Sato C, Marumo F. Clinical significance of elevated plasma endothelin concentration in patients with cirrhosis. Hepatology 1992; 16: 959.
  • 32
    Salo J, Francitorra A, Follo A, et al. Increased plasma endothelin in cirrhosis. Relationship with systemic endotoxemia and response to changes in effective blood volume. J Hepatol 1995; 22: 38998.
  • 33
    Uchida Y, Watanabe M. Plasma endothelin-1 concentrations are elevated in acute hepatitis and liver cirrhosis but not in chronic hepatitis. Gastroenterol Jpn 1993; 28: 66672.
  • 34
    Bernardi M, Gulberg V, Colantoni A, Trevisani F, Gasbarrini A, Gerbes AL. Plasma endothelin-1 and -3 in cirrhosis: relationship with systemic hemodynamics, renal function and neurohumoral systems. J Hepatol 1996; 24: 1618.
  • 35
    Notas G, Valatas V, Xidakis C, Kouroumalis A, Koulentaki M, Kouroumalis E. Circulating endothelin-1 and nitric oxide in primary biliary cirrhosis. Gut 1999; 44: A61.
  • 36
    Marasini B, Pipia C, DeValle G, et al. Vascular impairment in patients with primary biliary cirrhosis. Int J Microcirc Clin Exp 1995; 15: 759.
  • 37
    Babbs C, Haboubi NY, Mellor JM, Smith A, Rowan BP, Warnes TW. Endothelial cell transformation in primary biliary cirrhosis: a morphological and biochemical study. Hepatology 1990; 11: 7239.
  • 38
    Sinisalo J, Vanhanen H, Pajunen P, Vapaatalo H, Nieminen MS. Ursodeoxycholic acid and endothelial-dependent, nitric oxide-independent vasodilatation of forearm resistance arteries in patients with coronary heart disease. Br J Clin Pharmacol 1999; 47: 6615.
  • 39
    Arkenau HT, Stichtenoth DO, Frolich JC, Manns MP, Boker KH. Elevated nitric oxide levels in patients with chronic liver disease and cirrhosis correlate with disease stage and parameters of hyperdynamic circulation. Z Gastroenterol 2002; 40: 90713.
  • 40
    Albornoz L, Motta A, Alvarez D, et al. Nitric oxide synthase activity in the splanchnic vasculature of patients with cirrhosis: relationship with hemodynamic disturbances. J Hepatol 2001; 35: 4526.
  • 41
    Corpechot C, Carrat F, Bonnand AM, Poupon RE, Poupon R. The effect of ursodeoxycholic acid therapy on liver fibrosis progression in primary biliary cirrhosis. Hepatology 2000; 32: 11969.
  • 42
    Pares A, Caballeria L, Rodes J, et al. Long-term effects of ursodeoxycholic acid in primary biliary cirrhosis: results of a double-blind controlled multicentric trial. UDCA-Cooperative Group from the Spanish Association for the Study of the Liver. J Hepatol 2000; 32: 5616.
  • 43
    Angulo P, Batts KP, Therneau TM, Jorgensen RA, Dickson ER, Lindor KD. Long-term ursodeoxycholic acid delays histological progression in primary biliary cirrhosis. Hepatology 1999; 29: 6447.
  • 44
    Poupon R, Poupon RE. Treatment of primary biliary cirrhosis. Baillieres Best Pract Res Clin Gastroenterol 2000; 14: 61528.